Peter Thiel (Riccardo Savi/Sipa via AP Images)

Pe­ter Thiel joins fund­ing round for pep­tide drug play­er in lat­est swing at emerg­ing biotech mar­ket

For ven­ture cap­i­tal­ists work­ing in ear­ly-stage biotech, fail­ures are more com­mon than vic­to­ries as in­vestors search for nov­el path­ways to treat well-trod­den ther­a­peu­tic ar­eas. For the big-name in­vestors, that’s equal­ly true — but if your name’s Pe­ter Thiel, a cer­tain grav­i­ty and high ex­pec­ta­tions come with your mon­ey.

Bil­lion­aire tech en­tre­pre­neur and Face­book co-founder Thiel has joined a $35.4 mil­lion Se­ries B round for Pep­ti­log­ics, a pep­tide drug de­sign and de­vel­op­ment biotech, as the com­pa­ny looks to ex­pand on its lead an­ti-in­fec­tive can­di­date and tar­get more drugs for mar­ket.

Thiel’s Founders Fund, which has re­cent­ly made a se­ries of high-pro­file splash­es in the emerg­ing biotech field and pre­vi­ous­ly signed on as an in­vestor at Pep­ti­log­ics for an ear­li­er round, joins round leader Pre­sight Cap­i­tal. Pep­ti­log­ics in­tends to use its lat­est round to con­tin­ue fine-tun­ing its drug dis­cov­ery en­gine and ad­vance its pipeline can­di­dates, most no­tably PLG0206, a nov­el an­ti-in­fec­tive.

Pep­ti­log­ics’ “com­pu­ta­tion­al” plat­form pre-spec­i­fies tar­gets for its drug dis­cov­ery, then works back­ward through bio­med­ical da­ta to iden­ti­fy mol­e­cules — and lat­er ther­a­peu­tics — to hit those tar­gets, the com­pa­ny said in a re­lease. That strat­e­gy has caught in­vestors’ eyes as the po­ten­tial for nov­el path­ways for high­ly com­pet­i­tive ther­a­peu­tics ar­eas grows.

“Pep­ti­log­ics’ ap­proach chal­lenges tra­di­tion­al drug dis­cov­ery meth­ods by start­ing with a de­fined tar­get drug pro­file and work­ing back­wards to de­sign op­ti­mal, nov­el mol­e­cules,” Pre­sight Cap­i­tal’s Fabi­an Hansen said in a re­lease. “We be­lieve that scal­able ra­tio­nal de­sign, not ran­dom screen­ing, is the fu­ture of drug dis­cov­ery and Pep­ti­log­ics is well-po­si­tioned to lead the way.”

That in­ter­est has cer­tain­ly caught the eye of Thiel, who has made a se­ries of splashy en­tries in­to the field in re­cent years — some of them more suc­cess­ful than oth­ers.

As re­cent­ly as late No­vem­ber, Thiel shelled out $125 mil­lion as part of a Se­ries C fund­ing round to fu­el de­vel­op­ment at ATAI Life Sci­ences, a Berlin-based biotech that has as­sem­bled a port­fo­lio of com­pa­nies with psy­che­del­ic and non-psy­che­del­ic ap­proach­es to de­pres­sion, anx­i­ety and ad­dic­tion.

And it’s not just fund­ing, ei­ther: Al­so in No­vem­ber, Thiel jumped aboard as a board mem­ber at Ab­Cellera, a com­pa­ny part­ner­ing with Eli Lil­ly on Covid-19 an­ti­body de­vel­op­ment, as the com­pa­ny chas­es a ge­net­i­cal­ly en­gi­neered mouse mod­el that can de­vel­op hu­man an­ti­bod­ies.

The fate of those re­cent moves has yet to be seen, but at least one big Thiel in­vest­ment has re­cent­ly gone bel­ly up — a com­mon rit­u­al for sure in the world of emerg­ing biotech. Back in Au­gust, an­ti-ag­ing play­er Uni­ty Biotech­nol­o­gy flopped a ma­jor Phase II study in os­teoarthri­tis pain, jeop­ar­diz­ing the fu­ture of a com­pa­ny that once scored $200 mil­lion in ven­ture fund­ing from the likes of Thiel and Ama­zon helms­man Jeff Be­zos.

The com­pa­ny promised to be one of the first to ef­fec­tive­ly test the the­o­ry that clear­ing out old “senes­cent” cells could re­duce symp­toms as­so­ci­at­ed with ag­ing, but the ma­jor tri­al fail­ure cast doubt on Uni­ty’s promise in that field. This month, ARCH Ven­ture Part­ners’ Bob Nelsen, one of Uni­ty’s co-founders back in 2011, an­nounced he would step down from the board, join­ing pres­i­dent and co-founder Ned David, who is step­ping down at the end of the year, and an­oth­er board mem­ber, David Lacey, who is al­so de­part­ing.

BY­OD Best Prac­tices: How Mo­bile De­vice Strat­e­gy Leads to More Pa­tient-Cen­tric Clin­i­cal Tri­als

Some of the most time- and cost-consuming components of clinical research center on gathering, analyzing, and reporting data. To improve efficiency, many clinical trial sponsors have shifted to electronic clinical outcome assessments (eCOA), including electronic patient-reported outcome (ePRO) tools.

In most cases, patients enter data using apps installed on provisioned devices. At a time when 81% of Americans own a smartphone, why not use the device they rely on every day?

Image: Shutterstock

Eli Lil­ly asks FDA to re­voke EUA for Covid-19 treat­ment

Eli Lilly on Friday requested that the FDA revoke the emergency authorization for its Covid-19 drug bamlanivimab, which is no longer as effective as a combo therapy because of a rise in coronavirus variants across the US.

“With the growing prevalence of variants in the U.S. that bamlanivimab alone may not fully neutralize, and with sufficient supply of etesevimab, we believe now is the right time to complete our planned transition and focus on the administration of these two neutralizing antibodies together,” Daniel Skovronsky, Lilly’s CSO, said in a statement.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.

Osman Kibar (Samumed, now Biosplice)

Os­man Kibar lays down his hand at Sa­mumed, step­ping away from CEO role as his once-her­ald­ed an­ti-ag­ing biotech re­brands

Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its coffers and quietly changed its name to Biosplice Therapeutics.

Why the sudden rebrand?

“We did that for obvious reasons,” CFO and CBO Erich Horsley told Endpoints News. “The name Biosplice echoes our science much more than Samumed does.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.

Emmanuel Hanon (Viome)

Glax­o­SmithK­line’s head of vac­cine R&D is jump­ing to a well­ness com­pa­ny con­cen­trat­ing on the mi­cro­bio­me as re­ports of an ex­o­dus start to spread

Back in the fall of 2019, GlaxoSmithKline vaccine R&D chief Emmanuel Hanon had plenty of good things to say about a wellness company called Viome and CEO Naveen Jain. He was particularly interested in Viome’s technology for analyzing the gut microbiome and how that could intersect with new vaccine research.

Today, Hanon is jumping ship to join his collaborator as R&D chief as reports circulate of an exodus at GSK’s big vaccine group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.

J&J faces CDC ad­vi­so­ry com­mit­tee again next week to weigh Covid-19 vac­cine risks

The CDC’s Advisory Committee on Immunization Practices punted earlier this week on deciding whether or not to recommend lifting a pause on the administration of J&J’s Covid-19 vaccine, but the committee will meet again in an emergency session next Friday to discuss the safety issues further.

The timing of the meeting likely means that the J&J vaccine will not return to the US market before the end of next week as the FDA looks to work hand-in-hand with the CDC to ensure the benefits of the vaccine still outweigh the risks for all age groups.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.

Alan List, new Precision BioSciences CMO, in 2019 (Diane Bondareff/AP Images for Moffitt Cancer Center)

Eli Lil­ly-part­nered biotech taps star in­ves­ti­ga­tor Alan List as CMO — a year af­ter he re­signed from Mof­fitt over Chi­na scan­dal

After laying low for more than a year following a scandal that led to his ouster, former Moffitt Cancer Center CEO Alan List has emerged in the frontlines of biotech.

An expert in hematology and oncology drug development known as a lead investigator for Celgene’s blockbuster Revlimid, List is swapping “clinical trials consultant” for the chief medical officer title at Precision BioSciences — a Eli Lilly-partnered biotech boasting a new gene editing approach to cell and gene correction therapies.

Ex­clu­sive in­ter­view: Pe­ter Marks on why full Covid-19 vac­cine ap­provals could be just months away

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, took time out of his busy schedule last Friday to discuss with Endpoints News all things related to his work regulating vaccines and the pandemic.

Marks, who quietly coined the name “Operation Warp Speed” before deciding to stick with his work regulating vaccines at the FDA rather than join the Trump-era program, has been the face of vaccine regulation for the FDA throughout the pandemic, and is usually spotted in Zoom meetings seated in front of his wife’s paintings.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Near­ly a year af­ter Au­den­tes' gene ther­a­py deaths, the tri­al con­tin­ues. What hap­pened re­mains a mys­tery

Natalie Holles was five months into her tenure as Audentes CEO and working to smooth out a $3 billion merger when the world crashed in.

Holles and her team received word on the morning of May 5 that, hours before, a patient died in a trial for their lead gene therapy. They went into triage mode, alerting the FDA, calling trial investigators to begin to understand what happened, and, the next day, writing a letter to alert the patient community so they would be the first to know. “We wanted to be as forthright and transparent as possible,” Holles told me late last month.

The brief letter noted two other patients also suffered severe reactions after receiving a high dose of the therapy and were undergoing treatment. One died a month and a half later, at which point news of the deaths became public, jolting an emergent gene therapy field and raising questions about the safety of the high doses Audentes and others were now using. The third patient died in August.

“It was deeply saddening,” Holles said. “But I was — we were — resolute and determined to understand what happened and learn from it and get back on track.”

Eleven months have now passed since the first death and the therapy, a potential cure for a rare and fatal muscle-wasting disease called X-linked myotubular myopathy, is back on track, the FDA having cleared the company to resume dosing at a lower level. Audentes itself is no more; last month, Japanese pharma giant Astellas announced it had completed working out the kinks of the $3 billion merger and had restructured and rebranded the subsidiary as Astellas Gene Therapies. Holles, having successfully steered both efforts, departed.

Still, questions about precisely what led to the deaths of the 3 boys still linger. Trial investigators released key details about the case last August and December, pointing to a biological landmine that Audentes could not have seen coming — a moment of profound medical misfortune. In an emerging field that’s promised cures for devastating diseases but also seen its share of safety setbacks, the cases provided a cautionary tale.

Audentes “contributed in a positive way by giving a painful but important example for others to look at and learn from,” Terry Flotte, dean of the UMass School of Medicine and editor of the journal Human Gene Therapy, told me. “I can’t see anything they did wrong.”

Yet some researchers say they’re still waiting on Astellas to release more data. The company has yet to publish a full paper detailing what happened, nor have they indicated that they will. In the meantime, it remains unclear what triggered the events and how to prevent them in the future.

“Since Audentes was the first one and we don’t have additional information, we’re kind of in a holding pattern, flying around, waiting to figure out how to land our vehicles,” said Jude Samulski, professor of pharmacology at UNC’s Gene Therapy Center and CSO of the gene therapy biotech AskBio, now a subsidiary of Bayer.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pascal Soriot (AstraZeneca via YouTube)

Af­ter be­ing goad­ed to sell the com­pa­ny, Alex­ion's CEO set some am­bi­tious new goals for in­vestors. Then Pas­cal So­ri­ot came call­ing

Back in the spring of 2020, Alexion $ALXN CEO Ludwig Hantson was under considerable pressure to perform and had been for months. Elliott Advisers had been applying some high public heat on the biotech’s numbers. And in reaching out to some major stockholders, one thread of advice came through loud and clear: Sell the company or do something dramatic to change the narrative.

In the words of the rather dry SEC filing that offers a detailed backgrounder on the buyout deal, Alexion stated: ‘During the summer and fall of 2020, Alexion also continued to engage with its stockholders, and in these interactions, several stockholders encouraged the company to explore strategic alternatives.’

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.